Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

With the robust uptick in the applications of Bayesian external data borrowing, eliciting a prior distribution with the proper amount of information becomes increasingly critical. The prior effective sample size (ESS) is an intuitive and efficient measure for this purpose. The majority of ESS definitions have been proposed in the context of borrowing control information. Meanwhile, Bayesian borrowing is frequently conducted on the treatment effect scale to extrapolate evidence in pediatric or global trials. While many Bayesian models can be naturally extended to leveraging external information on the treatment effect scale, very little attention has been directed to computing the prior ESS in this setting. In this research, we bridge this methodological gap by extending the popular expected local information ratio (ELIR) ESS definition. We lay out the general framework, and derive the ESS for various types of endpoints and treatment effect measures. The desirable predictive consistency property of ELIR ESS is examined and found to only be preserved for the difference between two normal endpoints. The methods are implemented in R programs available on GitHub: https://github.com/squallteo/TrtEffESS.

Download full-text PDF

Source
http://dx.doi.org/10.1002/sim.70235DOI Listing

Publication Analysis

Top Keywords

treatment scale
12
prior effective
8
effective sample
8
sample size
8
elir ess
8
ess
6
prior
4
borrowing
4
size borrowing
4
treatment
4

Similar Publications

Objective: From October 18-20, 2022, the National Institutes of Health held a workshop to examine the state of the science concerning obesity interventions in adults to promote health equity. The workshop had three objectives: (1) Convene experts from key institutions and the community to identify gaps in knowledge and opportunities to address obesity, (2) generate recommendations for obesity prevention and treatment to achieve health equity, and (3) identify challenges and needs to address obesity prevalence and disparities, and develop a diverse workforce.

Methods: A three-day virtual convening.

View Article and Find Full Text PDF

Background: Intensive language-action therapy treats language deficits and depressive symptoms in chronic poststroke aphasia, yet the underlying neural mechanisms remain underexplored. Long-range temporal correlations (LRTCs) in blood oxygenation level-dependent signals indicate persistence in brain activity patterns and may relate to learning and levels of depression. This observational study investigates blood oxygenation level-dependent LRTC changes alongside therapy-induced language and mood improvements in perisylvian and domain-general brain areas.

View Article and Find Full Text PDF

Background: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography.

Methods: ETERNAL-LVO was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia.

View Article and Find Full Text PDF

Background: Poststroke cognitive impairment (PSCI) affects 30% to 50% of stroke survivors, severely impacting functional outcomes and quality of life. This study uses functional near-infrared spectroscopy (fNIRS) to assess task-evoked brain activation and its potential for stratifying the severity in patients with PSCI.

Method: A cross-sectional study was conducted at Nanchong Central Hospital between June 2023 and April 2024.

View Article and Find Full Text PDF

Background: Risk stratification in posterior circulation ischemic stroke (PCIS) is challenging. Although the Posterior Circulation Ischemic Stroke Outcome Score (PCISOS) was developed to address this, its utility in minor PCIS and in identifying homogeneous populations for clinical trials or treatment-responsive subgroups remains uncertain.

Methods: CHANCE-2 (Clopidogrel in High-Risk Patients With Acute Non-disabling Cerebrovascular Events-II) was a multicenter, randomized trial that enrolled patients with minor stroke or high-risk transient ischemic attack who carried CYP2C19 loss-of-function alleles.

View Article and Find Full Text PDF